SLC6A14 and neoplasm: The Erlotinib showed only one negative correlation with the SLC6A14 gene (Figure 6; Supplementary Table S7) that was upregulated in 15 tumor types including PRAD compared to pooled GTEx control group (Figure 1B; Supplementary Table S2), as well as in tumors with C2-C3 signature (Figure 5D; Supplementary Table S6).